Metoclopramide Medical Valley

Metoclopramide, the active ingredient in Metoclopramide Medical Valley, is a dopamine D2 receptor antagonist presented as an oral tablet for oral use. It treats nausea, vomiting and related gastrointestinal motility disorders in adults.\n\nGNH India supplies Metoclopramide Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide is used to manage conditions involving impaired gastric motility or nausea pathways.\n\n- Nausea and vomiting: reduces episodes of acute or chemotherapy‑induced nausea and vomiting.\n- Gastroparesis: enhances gastric emptying and improves related symptoms.\n- Gastro‑oesophageal reflux disease (GERD): alleviates reflux‑related nausea by promoting gastric clearance.\n- Migraine‑associated nausea: diminishes nausea accompanying migraine attacks.

Metoclopramide may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Drowsiness: mild sedation or fatigue.\n- Diarrhea: increased bowel movements.\n- Abdominal cramping: discomfort in the stomach area.\n- Headache: transient head pain.\n\nSerious or Rare Side Effects:\n- Extrapyramidal symptoms: muscle rigidity, tremor, or dystonia.\n- Tardive dyskinesia: irreversible involuntary movements with prolonged use.\n- Neuroleptic malignant syndrome: rare but life‑threatening hyperthermic reaction.

Before prescribing Metoclopramide, clinicians should consider several safety measures.\n\n- Assess renal function: dose adjustment may be needed in impairment.\n- Monitor for extrapyramidal symptoms: watch for muscle rigidity or tremor.\n- Avoid in patients with known hypersensitivity: discontinue if allergic reaction occurs.\n- Use with caution in the elderly: increased risk of confusion and falls.\n- Limit duration of therapy: prolonged use raises risk of tardive dyskinesia.\n- Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Metoclopramide can interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- CYP2D6 inhibitors (e.g., fluoxetine): may increase metoclopramide plasma levels.\n- Anticholinergic agents: additive anticholinergic effects can worsen constipation.\n- Other dopamine antagonists: heightened risk of extrapyramidal reactions.\n\nModerate Interactions (Monitor Closely):\n- CNS depressants (e.g., benzodiazepines): may enhance sedation.\n- Macrolide antibiotics (e.g., erythromycin): possible alteration of gastrointestinal motility.\n- Serotonergic agents (e.g., ondansetron): potential for serotonin syndrome when combined.